How to identify Hydroxychloroquine’s ON and OFF targets to design a more potent molecule with enhanced clinical efficacy and reduced retinal toxicity in comparison to HCQ?
Inoviem Scientific offers a range of services tailored to the needs of drug discovery, preclinical and clinical development.
We help researchers better meet those requirements essential for the validity of an experiment, accelerate drug development and achieve clinical trial objectives.
Understand the mode of action of your compound
The ultimate understanding of the Mode of Action (MoA) of your compound resides with taking a patient-centric approach
Validate targets in the study model
Compound pharmacology is always shown in a relevant model, whether cellular or animal. It is important to identify and validate the primary target in the very same model.
Choose the compound for development
With greater emphasis on translational pharmacology, any number of compounds can be profiled, and we can identify within four weeks of study which one of these offers the best ‘druggability’ to move forward into development.
Stratify different patient groups
Inoviem harnesses its study power to locate and identify within the whole population the right patient subset who would respond to the compound.
Identify secondary targets
If you suspect that a secondary target may be problematic, we can quickly identify whether it is beneficial to the indication or produces side-effects.
Validate target in targeted organism
Our robust empirical approach enables you to salvage a failed compound by finding a new indication for it.
Define the indication
When your promising compound has failed in its primary indication, we can fast-track you to identifying a condition that would be more efficient.
Inoviem’s translational pharmacology strategy goes beyond genomic approaches, to give you more information than just the genetic function of a disease.
Our expertise in translational pharmacology
Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies developed in a pathological and physiological environment that uses human tissue.
Our approach to working directly on non-modified human tissue means that we eliminate the need for modeling and its significant drawback of failing to take account of the natural environment in which a drug will have its beneficial effect.
We work within a natural environment and provide you with critical data without biasing the drug development process.
This results in a lower risk of drugs reaching the market with unexpected undesired effects or a loss of therapeutic activity.
Our innovative approach:
Rather than working on any type of pharmacology in an animal or cellular model, the work is performed directly on human tissue.
Advantages of approach
Inoviem highly recommends adopting a translational pharmacology strategy at the inception of any project, as it saves time and money.
How we work with clients
Inoviem develops new methodologies, approaches and/or technologies specifically tailored to solve each client’s unique problem.
As our label-free technologies perform drug-target MoA under physiological environments and in human samples, the test compound preserves its original structure as well as the exact same molecular structure that would be used in therapy.
Identify the mode of action of your compound
From preclinical to clinical
Adopt a robust solution that can ensure the success of your Phase II study and accompany you in achieving the success of your drug candidate in Phase III
Identify a cohort of patients responding to your therapy
Inoviem, a bioanalytical Contract Research Organization (CRO), enables drug developers to gain greater precision in the understanding of a compound’s clinical Mode of Action (MoA), so that a drug candidate can move rapidly to clinical trials.
Our approach is based on the simple idea that current technologies fail to take into account the natural environment in which a drug will have its beneficial effect…
Inoviem Scientific’s core values are deeply ingrained in our past, present and future; they guide us in our daily work…
At Inoviem, we are committed to contributing work that upholds the quality of life and well-being of individuals…
Bioparc 3, 850 boulevard Sébastien Brant,
Tel. +33 (0)9 72 56 94 99
|cookielawinfo-checkbox-advertisement||1 year||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".|
|cookielawinfo-checkbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".|
|cookielawinfo-checkbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".|
|cookielawinfo-checkbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".|
|elementor||never||This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.|
|_ga||2 years||This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.|
|_ga_61RXK9ZCWR||2 years||This cookie is installed by Google Analytics.|